This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK (
Gilead Sciences(GILD - Get Report) was the best-performing stock in the
S&P 500 on Thursday morning.
The S&P 500 was dropping 1.74 points, or 0.13%, to 1,383.40.
Shares of Gilead Sciences were rising 14.67% Thursday morning to $53.45. The stock is rising based on results from Gilead Sciences' hepatitis C tests. The company's
"Electron" study of GS-7977 has an early cure rate of 88%.
Gilead Sciences has an estimated price-to-earnings ratio for next year of 12.39 times; the average for biotechnology companies is 29.95. For comparison,
Amgen(AMGN) has a lower forward P/E of 10.01;
Celgene's(CELG) forward P/E is 14.
Twenty-six of the 33 analysts who cover Gilead Sciences rated it buy; seven analysts gave the stock a hold rating.
TheStreet Ratings gives Gilead Sciences an A- grade with a buy rating and
$57.34 price target. The stock has risen 30.64% year to date.